Cardiff Oncology (formerly Trovagene Inc.) Revenue and Competitors
Estimated Revenue & Valuation
- Cardiff Oncology (formerly Trovagene Inc.)'s estimated annual revenue is currently $15M per year.
- Cardiff Oncology (formerly Trovagene Inc.)'s estimated revenue per employee is $300,000
- Cardiff Oncology (formerly Trovagene Inc.)'s total funding is $80.5M.
Employee Data
- Cardiff Oncology (formerly Trovagene Inc.) has 50 Employees.
- Cardiff Oncology (formerly Trovagene Inc.) grew their employee count by 19% last year.
Cardiff Oncology (formerly Trovagene Inc.)'s People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Finance and Corporate Secretary | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | Director Research & Development | Reveal Email/Phone |
5 | Associate Director, Clinical Operations | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | Senior Scientist Bioinformatics | Reveal Email/Phone |
8 | Senior Scientist, Bioinformatics | Reveal Email/Phone |
9 | Clinical Laboratory Technician | Reveal Email/Phone |
Cardiff Oncology (formerly Trovagene Inc.) Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Cardiff Oncology (formerly Trovagene Inc.)?
Trovagene is a clinical-stage, precision medicine oncology therapeutics company. Trovagene’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Our goal is to overcome resistance, extend duration of response and increase overall survival.
keywords:N/A
$80.5M
Total Funding
50
Number of Employees
$15M
Revenue (est)
19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cardiff Oncology (formerly Trovagene Inc.) News
SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need (including KRAS-mutated colorectal cancer, pancreatic canc ...
Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative •Pfizer invests $15 million in Cardiff Oncology common shares •Adam Schayowitz, Ph.D., MBA, Vice President, Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and M ...
Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival -8 of 19 (42%) patients treated per protocol at the recommended Phase 2 dose (RP2D) of onvansertib 15 mg/m2 who were evalua ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.4M | 50 | -7% | N/A |
#2 | $4.8M | 50 | 9% | N/A |
#3 | $8.8M | 50 | 11% | N/A |
#4 | $8.2M | 50 | N/A | N/A |
#5 | $5.3M | 50 | 9% | $3M |